BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1428 related articles for article (PubMed ID: 15788128)

  • 21. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells.
    Mukaide H; Adachi Y; Koike-Kiriyama N; Suzuki Y; Minamino K; Iwasaki M; Tsuda M; Nakano K; Koike Y; Shigematsu A; Kamiyama Y; Ikehara S
    Int J Oncol; 2007 Jun; 30(6):1309-15. PubMed ID: 17487350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
    Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M
    Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats.
    Koike Y; Adachi Y; Suzuki Y; Iwasaki M; Koike-Kiriyama N; Minamino K; Nakano K; Mukaide H; Shigematsu A; Kiyozuka Y; Tubura A; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Feb; 25(2):385-91. PubMed ID: 17284650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental study of the inhibiting effect of the lentiviral vector mediated herpes simplex virus-thymidine kinase/ganciclovir on GVHD].
    Xu KL; Zhu F; Du B; Gao F; Cheng H; Pan XY
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):303-7. PubMed ID: 17877157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of HGF on graft-versus-host disease and graft-versus-leukemia after allogeneic bone marrow transplantation in acute lymphoblastic leukemia mice].
    Xia YJ; Gao QP; Wan CC; Cheng FJ; Liu ZX; Guo RC
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):404-7. PubMed ID: 16251021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intra-bone marrow bone marrow transplantation plus donor lymphocyte infusion.
    Nakamura K; Inaba M; Sugiura K; Yoshimura T; Kwon AH; Kamiyama Y; Ikehara S
    Stem Cells; 2004; 22(2):125-34. PubMed ID: 14990852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of graft-versus-host disease by intra-bone marrow injection of donor T cells.
    Fukui J; Inaba M; Ueda Y; Miyake T; Hosaka N; Kwon AH; Sakaguchi Y; Tsuda M; Omae M; Kamiyama Y; Ikehara S
    Stem Cells; 2007 Jun; 25(6):1595-601. PubMed ID: 17446564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
    Elkin G; Prigozhina TB; Slavin S
    Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mixed hematopoietic chimerism for preventing graft-versus-host disease in mice receiving rat bone marrow transplantation.
    Pei FY; Li CF; Tang XF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Jul; 23(7):709-13. PubMed ID: 12865228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Study of graft-versus -leukemia activity of gamma-ray irradiated haplomismatched donor lymphocytes infusion].
    Zhang L; Guo K; Dong B; Luo Q
    Zhonghua Xue Ye Xue Za Zhi; 2000 Feb; 21(2):81-3. PubMed ID: 11876964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.